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ABSTRACT
Introduction An unbalanced intestinal microbiota 
may mediate activation of the inflammatory pathways 
seen in psoriatic arthritis (PsA). A randomised, placebo-
controlled trial of faecal microbiota transplantation (FMT) 
infused into the small intestine of patients with PsA with 
active peripheral disease who are non-responsive to 
methotrexate (MTX) treatment will be conducted. The 
objective is to explore clinical aspects associated with FMT 
performed in patients with PsA.
Methods and analysis This trial is a randomised, 
two-centre stratified, double-blind (patient, care 
provider and outcome assessor), placebo-controlled, 
parallel-group study. Eighty patients will be included 
and randomised (1:1) to either placebo (saline) or FMT 
provided from an anonymous healthy donor. Throughout 
the study, both groups will continue the weekly self-
administered subcutaneous MTX treatment, remaining 
on the preinclusion dosage (15–25 mg/week). The 
clinical measures of psoriasis and PsA disease activity 
used include the Short (2-page) Health Assessment 
Questionnaire, the Dermatology Quality of Life Index, 
the Spondyloarthritis Research Consortium of Canada 
Enthesitis Index, the Psoriasis Area Severity Index, a 
dactylitis digit count, a swollen/tender joint count (66/68), 
plasma C reactive protein as well as visual analogue 
scales for pain, fatigue and patient and physician global 
assessments. The primary end point is the proportion 
of patients who experience treatment failure during the 
6-month trial period. The number of adverse events will be 
registered throughout the study.
Ethics and dissemination This is a proof-of-concept 
clinical trial and will be performed in agreement with Good 
Clinical Practice standards. Approvals have been obtained 
from the local Ethics Committee (DK-S-20150080) and the 
Danish Data Protection Agency (15/41684). The study has 
commenced in May 2017. Dissemination will be through 
presentations at national and international conferences 
and through publications in international peer-reviewed 
journal(s).
Trial registration number NCT03058900; Pre-results.
InTRoduCTIon  
Emerging data suggest a causal relation-
ship between the intestinal microbiota and 
spondyloarthritis (SpA), thus linking dysbi-
osis of the complex microbial communities 
with SpA pathogenesis.1–5 Psoriatic arthritis 
(PsA) is one of five SpA categories in adults 
which also include ankylosing spondylitis, 
undifferentiated arthritis, reactive arthritis 
and arthritis associated with inflammatory 
bowel disease (IBD). While the association 
between the gut and the latter two disorders 
is well established,6 only very recently, studies 
evaluating the faecal microbiota and the 
presence of subclinical gut inflammation in 
patients with PsA have coupled this disease 
to a perturbation of the intestinal microbiota 
composition.7–12 
PsA is a distinct, multifaceted inflamma-
tory disease with a diverse clinical spectrum 
Strengths and limitations of this study
 ► This is a double-blind, randomised, placebo-con-
trolled trial.
 ► Subcutaneously administered methotrexate treatment.
 ► The primary end point is based on shared deci-
sion-making between patient and physician.
 ► No feasibility data regarding faecal microbiota trans-
plantation in patients with rheumatic diseases were 
available when the trial was designed.
 ► A limitation of the study is that the content of 
the faecal transplant suspension cannot be fully 
standardised.
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and a varied disease course.13 The clinical manifesta-
tions include peripheral arthritis, enthesitis and/or 
spondylitis combined with more or less severe psoriatic 
skin involvement, nail psoriasis and dactylitis.14 Nearly 
half of the patients with both early and established PsA 
also present with extramusculoskeletal manifestations, 
which can include bowel (16%), ocular, cardiovascular 
or urogenital involvement.15 Without disease-modifying 
intervention, 40%–60% of patients with PsA will develop 
erosive and deforming joint damage within a few years 
of disease onset.16 Methotrexate (MTX) has long been 
the preferred conventional synthetic disease-modifying 
antirheumatic drug (csDMARD) for initial therapy.17 
However, the evidence for MTX in PsA is poor, and a 
substantial number of patients does not benefit from 
such treatment.18 Currently, other treatment options 
may include biological agents such as tumour necrosis 
factor (TNF-α) inhibitors aiming to block some of the 
downstream molecular pathways driving the disease.19 
Still, these drugs do not target the cause of PsA, which is 
believed to be multifactorial comprising genetic, immu-
nological and environmental factors.20 The interplay 
between these complex aetiological factors has yet to be 
fully understood.21 22
The classic pathophysiological concept of PsA is that 
it is an autoimmune disease of the skin and joints and 
that the pathological processes at both sites are driven 
by inflammatory responses involving the innate immune 
system, natural killer cells, T cells and the expression of 
proinflammatory cytokines, including TNF-α, interleukin 
(IL)-1, interferon-γ, IL-6, IL-12, IL-15, IL-18 and the 
IL-17/IL-23 axis.23–27 However, although microbial agents 
including dormant bacteria, mycobacteria, bacterial prod-
ucts and viral antigens have been implicated as potential 
initiators,28 29 the true pathophysiological factors trig-
gering the dysregulated immunological cascade under-
lying the disease remain to be identified.
Intriguingly, it has recently been suggested that 
mucosal sites exposed to a high load of bacterial anti-
gens, in particular the gastrointestinal tract, may repre-
sent the initial site of immunological tolerance break in 
PsA.30 Indeed, under normal conditions the host and the 
microbiota live in harmony and benefit from their mutu-
alistic relationship. However, alterations of the normal 
intestinal microbiota can affect mucosal immunity which, 
in turn, can induce local inflammation and elicit systemic 
effects at distant sites.31 Mechanisms through which the 
intestinal microbiota may be involved in the pathogen-
esis of PsA include an abnormal activation of the gut-as-
sociated lymphoid tissue,32 a decrease in regulatory T-cell 
activity33 and/or an altered mucosal permeability thus 
compromising the capacity of the intestine to provide 
adequate containment of luminal microorganisms and 
molecules.34 35 In support of these theories, several 
studies have documented subclinical gut inflammation in 
patients with PsA.36–41 Moreover, a recent study reported 
that several intestinal bacteria including Akkermansia and 
Ruminococcus were practically absent in patients  with  PsA. 
These commensal bacteria are, in fact, known to play an 
important role in maintaining gut homeostasis.42
Rationale
If the gut microbiota is the initiator and/or mediator of 
the common inflammatory pathways seen in PsA,8 modi-
fying the intestinal microbiota could be a novel treatment 
strategy for this disease.1–3 43 Faecal microbiota trans-
plantation (FMT) is currently being used to restore the 
balance of the intestinal microbiota.44 45 Particularly, this 
procedure has demonstrated >90% clinical resolution of 
recurrent or refractory Clostridium difficile infections.46–50 
Also, multiple FMTs seem to be able to induce remission 
in patients with IBD.51 Due to these results, FMT is now 
being tested as a potential novel treatment for other 
gastrointestinal and extraintestinal diseases.52 To the 
best of our knowledge, no study has yet ascertained the 
efficacy and safety of FMT in patients with inflammatory 
rheumatic diseases.
Evidence-based research
To avoid waste of research, no new studies should be initi-
ated without a systematic review of the existing evidence.53 
We performed a pragmatic search in the biomedical liter-
ature via Pubmed combining different related MeSH 
terms: (‘Microbiota’(Mesh) OR ‘Fecal Microbiota Trans-
plantation’(Mesh) OR ‘Faecal Microbiota Transplanta-
tion’(Mesh) OR ‘Gastrointestinal Microbiome’(Mesh)) 
AND (arthritis(tiab) OR ‘Arthritis’(Mesh) OR ‘Arthritis, 
Psoriatic’(Mesh) OR ‘Arthritis, Reactive’(Mesh) OR 
‘Spondylarthritis’(Mesh) OR ‘Arthritis, Gouty’(Mesh) 
OR ‘Arthritis, Rheumatoid’(Mesh) OR ‘Psoria-
sis’(Mesh)). From the search revealing 122 citations, it 
became clear that the majority of papers were reviews/
editorials (74 (61%)), where the overall conclusion was 
that the main challenges are to uncover the cause-effect 
relationship between the intestinal microbiota and rheu-
matic diseases, and to investigate the potential of micro-
biome-targeting strategies.1 3 5 6 20 32 43 54–60 Also from the 
published literature it became evident that to date only 
nine clinical interventional studies trying to modify the 
intestinal microbiota in patients with arthritis have been 
performed: one study in patients with SpA (n=63),61 and 
one study in enthesis-related arthritis (n=8) reported 
no beneficial effects of probiotic therapy,62 whereas one 
study in juvenile idiopathic arthritis testing exclusive 
enteral nutrition administration (n=7) found a moderate 
anti-inflammatory effect on active joints.63 Five place-
bo-controlled trials of probiotic therapy in patients with 
rheumatoid arthritis64–68 (sample size between 26 and 60 
patients) reported mixed results.69 However, two of these 
studies demonstrated positive clinical effects of probi-
otic therapy, which included improvement in Health 
Assessment Questionnaire (HAQ)-Didability Index pain 
scale,65 improvement in the Disease Activity Score of 28 
joints and improvement on the C reactive protein (CRP) 
concentrations.66 No clinical trials performing FMT on 
patients with arthritis were identified.
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objective
The objective of this randomised trial is to explore whether 
FMT is more effective than placebo in reducing disease 
activity in patients with PsA with active peripheral arthritis 
concomitantly treated with weekly subcutaneously admin-
istered MTX. In addition, extensive bacterial taxonomic 
and metagenomic analyses will be performed on faecal 
samples before and after the FMT to get an indication of 
the functional capacity of the intestinal microbiota.
METhodS And AnAlySIS
Trial design
This is a randomised, patient, physician and outcome-as-
sessor blinded, placebo-controlled, 6-month trial, which 
will be followed by an open-label extension period for a 
minimum of 2 years. Patients will be randomly assigned in 
a 1:1 ratio to receive FMT or placebo (sham procedure). 
Outcome assessment will be based on follow-up by a rheu-
matologist and is scheduled to occur after 3 and 6 months 
(with the latter being the primary end point evaluation) 
(see figure 1 and figure 2).
Participants
Recruitment will take place at Danish rheumatology 
outpatient clinics, and patients fulfilling the eligibility 
criteria will be offered participation. No treatment 
with biologics within 6 months, and no systemic and/
or local intra-articular or peritendinous steroid injec-
tions, or non-MTX csDMARD treatment, or antibiotics 
are allowed within 3 months prior to inclusion. Non-ste-
roidal anti-inflammatory drugs (NSAIDs) must be paused 
within 14 days of study inclusion. Patients, who do not 
wish to participate, will be characterised by sex and age. 
The recruitment has commenced in May 2017 and will 
continue until 2019.
Patients with psoriatic arthritis
A total of 80 patients with PsA will be enrolled, and they 
will have to meet the following eligibility criteria:
Figure 1 Flow diagram of the randomised, placebo-controlled trial. FMT, faecal microbiota transplantation.
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Inclusion criteria
 ► Diagnosis of PsA according to the Classification 
Criteria for Psoriatic Arthritis.70
 ► Presence of active peripheral arthritis defined 
as ≥3 swollen joints.
 ► Subcutaneously administered MTX treatment 
(≥15 mg/week (maximal tolerable dosage)) for a 
minimum of 3 months prior to study inclusion.
 ► Age 18–70 years.
Exclusion criteria
 ► Other inflammatory rheumatic diseases than PsA.
 ► Current axial disease activity or severe peripheral joint 
activity demanding immediate change of treatment or 
contraindicating placebo treatment for 6 months.
 ► IBD, coeliac disease, food allergy or other intestinal 
diseases.
 ► Current cancer or severe chronic infections.
 ► History of severe MTX toxicity or allergic reactions.
 ► Biological treatment within 6 months prior to 
inclusion.
 ► Non-MTX DMARD treatment within 3 months prior 
to inclusion.
Figure 2 Participation timeline and characteristics of each visit. FMT, faecal microbiota transplantation; PsA, psoriatic arthritis.
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 ► Systemic and/or local intra-articular or peritendinous 
steroid injections within 3 months prior to inclusion.
 ► NSAIDs within 14 days prior to inclusion.
 ► Antibiotics within 3 months prior to inclusion.
 ► Pregnant or breastfeeding women.
 ► Not wishing to participate or unsuited for project 
evaluation.
Stool donors
The stool donor corps will consist of four anonymous (to 
the recipient) donors who must be healthy as assessed 
by a screening questionnaire, and be active members 
of the Danish blood donor corps, age 25–55 years, body 
mass index between 18.5 and 25 kg/m2 and an average 
alcohol intake <7 (women) or <14 (men) units per week. 
No alcohol intake within a week of donation is allowed, 
and no systemic medication including antibiotics and 
NSAIDs 6 months prior to the donation are allowed. The 
donor must eat a balanced diet (no extreme low-calorie 
or high-calorie diets), and must not be in a stressful life 
period. Before joining the stool donor corps, each poten-
tial donor will go through a screening process including 
stool analyses for faecal calprotectin and enteric patho-
gens (Aeromonas, Campylobacter, C. difficile, diarrhoeagenic 
Escherichia coli, Salmonella, Shigella, Vibrio, Yersinia enteroco-
litica and multidrug-resistant bacteria), parasites including 
microscopy of ova and cysts, Entamoeba histolytica/dispar 
(DNA), Cryptosporidium (DNA) and Giardia (DNA), sapo-
virus (RNA), rotavirus (RNA), human astrovirus (RNA), 
human adenoviruses (DNA) and noroviruses (RNA), a 
Helicobacter pylori breath test, blood tests for CRP) (accept-
able level: <6.0 mg/L), white blood cell count (accept-
able range: 3.50–8.80×109/L), haemoglobin (acceptable 
range: 8.3–10.5 mmol/L), albumin (acceptable range: 
36–50 g/L), alanine aminotransferase (acceptable range: 
10–70 U/L), estimated glomerular filtration rate (accept-
able level: >59 mL/min) and coeliac disease, and blood 
test for infectious agents including current infection with 
Epstein-Barr virus (IgM) and cytomegalovirus (IgM), 
hepatitis A, B, C and E, tuberculosis (QuantiFERON 
TB-Gold test), syphilis, HIV(ab HTLV1/2), E. histolytica 
(antibodies) and Strongyloides (antibodies), and a urine 
test for Chlamydia Trachomatis and Neisseria gonorrhoeae 
(DNA/RNA). After passing the screening tests, the donor 
will donate stool for the next month after which, the 
donor will have to pass the screening programme once 
more before the stool can be released for transplantation.
Interventions
Overall study interventions
The FMT will be an add-on strategy for patients with PsA 
with active joint disease despite ongoing treatment with 
weekly subcutaneously administered MTX. Therefore, all 
enrolled patients with PsA will continue their MTX treat-
ment throughout the study, and they will remain on the 
same individual dosage that they received at the time of 
study inclusion (a minimum of 15 mg/week cf. the patient 
inclusion criteria) in addition to folic acid supplement. 
Paracetamol and tramadol in recommended dosages are 
allowed during the trial but no NSAIDs can be taken.
Active and sham comparator
Patients will be randomised into two groups with an alloca-
tion ratio of active-to-placebo treatment of 1:1. The active 
comparator group (n=40) will have an FMT with healthy 
donor faeces-suspension (250 mL) containing 50 g donor 
faeces, saline (NaCl 0.9%) and glycerol (10%), whereas 
the sham comparator group (n=40) will be treated with 
an identical appearing sham procedure where the trans-
plant solution will consist of 250 mL brown coloured 
(brown food colourant) isotonic saline (NaCl 0.9%).
Preparing the FMT suspension
Donors will collect faeces at home and transport it in a 
cooling bag to the study site within 1 hour. Faeces will be 
sieved to remove particulate material, followed by dilu-
tion in sterile saline (0.9% NaCl) and 10% glycerol. The 
FMT suspension will be stored at −80°C until use. On the 
day of the FMT transplantation, the transplant suspen-
sion (250 mL) will be thawed to 37°C and subsequently 
apportioned into five 50 mL syringes.
FMT procedure
The FMT will take place within 14 days (preferably 7 
days) of the baseline clinical examination. The evening 
prior to the FMT, patients will take one dose (40 mg) of 
oral proton-pump inhibitor. They will meet at the Depart-
ment of Gastroenterology after a 6-hour fast. A total of 
250 mL transplant suspension (active or placebo) will be 
installed in the duodenum using an oral-duodenal tube. 
The correct placement of the tube will be confirmed 
using gastroscopic guidance.
Treatment strategy for non-responders
Patients who present with increased or unacceptable 
disease activity during the 6-month trial period will, 
depending on the clinical presentation, be offered 
another treatment strategy, which may include local 
intra-articular steroid injections, change to another 
csDMARD or biological treatment. If the patient accepts 
such treatment changes, this will be characterised as FMT 
treatment failure according to the primary outcome defi-
nition (one intra-articular steroid injection is allowed).
MTX toxicity and dropouts
Blood tests for MTX toxicity will be performed in accor-
dance with our current clinical practice. In case of MTX 
toxicity, severe side effects, pregnancy or occurrence of 
infectious disease or other diseases that contraindicate 
MTX treatment, MTX dosage will be decreased or the 
treatment will be paused. These patients will remain in 
the study (unless their condition contraindicates this), 
and they will be analysed as members of the treatment 
group to which they were randomised using intention-to-
treat-type analyses.
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Collection of faecal samples and metagenomics analysis
Fresh faecal samples will be collected by the patient at 
home using an EasySampler stool collection kit within 
24 hours prior to the study visit. Samples will be stored in 
the patient’s freezer until transported to the study site. 
During transport, samples will be kept on ice in a cooling 
bag. On arrival to the study site, samples will immedi-
ately be transferred to the biobank and stored at −80°C. 
Bacterial DNA will be extracted from the faecal samples 
following established standard protocols including bead 
beating using a NucleoSpin soil kit (Macherey-Nagel, 
Germany) according to manufacturer’s instructions. 
DNA will be sequenced using the BGISEQ-500 Plat-
form, which was recently benchmarked against the 
Illumina platforms showing excellent intraplatform 
reproducibility and less GC bias than observed using the 
Illumina platforms.71 The faecal metagenomics bioin-
formatics analyses will be performed using comprehen-
sive pipelines including the assembly of metagenomics 
linkage groups/metagenomics species,72 73 taxonomic 
annotation and extensive functional analyses based on 
metagenomic species, which provides a superior dataset 
compared with the conventional analyses based on the 
total gene pool.74
Intestinal permeability test
After an overnight fasting, patients will provide a urine 
sample before ingesting 100 mL water containing 10 g of 
lactulose and 5 g of D-mannitol. All the urine passed in 
the subsequent 5 hours will be collected into a 2 L plastic 
container containing 1 mL of chlorohexidine (20 mg/
mL) as a preservative. After 3 and 5 hours, the volume of 
the urine will be measured and a small volume (10 mL) 
will be preserved and stored at −80°C until analysis. No 
food or drinking (except for water) will be allowed during 
the test.75 76
outcomes
Primary outcome measure
Treatment failure (time frame: 6 months (±14 days)).
Proportion of patients in each group who experience 
treatment failure according to shared decision-making 
between patient and rheumatologist defined as at least 
one of the following:
 ► Need for more than one intra-articular glucocorticoid 
injection due to disease activity.
 ► Need for change to other csDMARDs (eg, oral lefluno-
mide or sulfasalazine) according to the updated 
Danish treatment guideline due to disease activity.
 ► Need for biologic treatment according to the updated 
Danish treatment guideline due to severe disease 
activity.
Secondary outcome measures
Change from baseline in the Short (2-page) HAQ77 78 
(time frame: baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 
months (±7 days), 6 months (±14 days)).
Change from baseline in the Dermatology Life Quality 
Index Questionnaire79 (time frame: 1 week, 2 weeks, 3 
weeks, 4 weeks, 3 months (±7 days), 6 months (±14 days)).
Changes from baseline in patient reported gastrointes-
tinal side effects (time frame: 1 week, 2 weeks, 3 weeks, 4 
weeks, 3 months (±7 days), 6 months (±14 days)).
Other non-gastrointestinal patient reported side effects 
(time frame: 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months 
(±7 days), 6 months (±14 days)].
Proportion of patients in each group achieving the 
American College of Rheumatology (ACR)80 Response 
Criteria (time frame: 3 months (±7 days), 6 months (±14 
days)):
I. ACR20 response criteria81
II. ACR50 response criteria82
III. ACR70 response criteria.82
Proportion of patients in each group achieving the 
Psoriatic Arthritis Response Criteria80 (time frame: 3 
months (±7 days), 6 months (±14 days)).
Change from baseline in the Spondyloarthritis Research 
Consortium of Canada Enthesitis Index68 in the subset of 
patients who have enthesitis at baseline (time frame: 3 
months (±7 days), 6 months (±14 days)).
Change from baseline in the Psoriasis Area Severity 
Index (PASI)83 in the subset of patients who have skin 
psoriasis at baseline (time frame: 3 months (±7 days), 6 
months (±14 days)).
Change from baseline in the number of digits affected 
with dactylitis in the subset of patients who have dactylitis 
at baseline (time frame: 3 months (±7 days), 6 months 
(±14 days)).
Number of adverse events (AEs) in each group (time 
frame: 6 months (±14 days)).
Number of AEs in each group leading to discontinua-
tion (time frame: 6 months (±14 days)).
Number of patients with at least one AE in each group 
(time frame: 6 months (±14 days)).
Tertiary (exploratory secondary) outcomes: proportion of 
patients in each group achieving changes in plasma 
CRP, changes in tender point count,84 changes in faecal 
bacteria composition and metabolism, changes in intes-
tinal permeability, changes in plasma orosomucoid, 
changes in plasma and faecal calprotectin,85 changes 
in serum 1,25-dihydroxyvitamin D, changes in cardio-
vascular risk factors including body mass index, blood 
pressure, plasma triglyceride, plasma low-density lipo-
protein-cholesterol, plasma high-density lipoprotein-cho-
lesterol, plasma total-cholesterol and haemoglobin A1c 
levels, changes in specific circulating inflammatory 
markers (ie, cytokines, adipokines and chemokines) and 
macroscopic and microscopic inflammatory changes of 
the colonic mucosa (see table 1).
Safety
The most frequently reported adverse events (AEs) 
related to FMT are vomiting, belching, mild diarrhoea, 
abdominal cramping, transient fever and elevated CRP 
on the day of the procedure.86 A recent systematic review 
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Table 1 Protocol schedule of forms and procedures.
Activity/assessment
Prestudy 
screening
Visit 1
Baseline
Weeks
1, 2 and 3
Visit 2
1 month
Visit 3
3 months
Visit 4
6 months
Patients n = ? n=80 n=all n=all n=all n=all
Screening log x
Inclusion/exclusion form x
Consent form x
Randomisation x
Study-composed questionnaire x x x x x
Patient global (VAS 0– 100 mm) x x x x x
Patient fatigue (VAS 0–100 mm) x x x x x
Patient pain (VAS 0–100 mm) x x x x x
HAQ x x x x x
BASDAI x x x
BASFAI x x x
DLQI x x x x x
Gastrointestinal symptom diary x x x x x
Eating habits questionnaire x
Clinical examination 
  Height (m) x
  Weight (kg) x x x
  Blood pressure (mm Hg) x x x
  Psoriasis Area Severity Index x x x
  SPARCC Enthesitis Score x x x
  Swollen joint count (66) x x x
  Tender joint count (68) x x x
  Doctors global (VAS 0–100 mm) x x x
  BASMI x x x
  Tender point count x x x
Interview (AEs) x x x
Blood sample analysis 
  C reactive protein (mg/L) x x x x
  Orosomucoid (g/L) x x x x
  Calprotectin x x x x
  1,25-Dihydroxyvitamin D (nmol/L) x x x x
  TSH (mIU/L) x x
  Hgb (mmol/L) x x
  Triglyceride (mmol/L) x x
  LDL-cholesterol (mmol/L) x x
  HDL-cholesterol (mmol/L) x x
  Total cholesterol (mmol/L) x x
  Haemoglobin A1c (mmol/mol) x x
  HLA-B27 status (±) x
  Serology tests for Yersinia, Campylobacter, 
Salmonella (±) 
x
Faecal calprotectin x x x x
Faecal microbiota analysis x x x x
Continued
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on the AEs of FMT identified 50 relevant studies with a 
total of 1089 patients. In this review, the incidences of 
serious adverse events (SAEs) for FMT were 2.0% and 
6.1% for upper and lower gastrointestinal routes, respec-
tively. The SAEs that probably or possibly were related to 
FMT included infections (0.7%), IBD flare (0.6%), death 
(0.3%), autoimmune diseases and FMT procedure-re-
lated injury.87 Although most of the patients included in 
this review suffered from severe gastrointestinal diseases 
(C. difficile infection and/or IBD), these findings warrant 
caution when performing FMT, especially when intro-
ducing the procedure in a new patient population. In 
addition, the potential long-term side effects following 
FMT remains largely unknown.88 Still, when strict donor 
screening is conducted and the procedure is performed 
by experienced practitioners, FMT is in general consid-
ered safe, and even elderly patients with a poor medical 
condition and multiple comorbidities as well as immu-
nosuppressed patients have been proven to tolerate the 
FMT procedure well.89–93
In the present study, we will carefully monitor and 
evaluate safety by means of open assessment of AEs. All 
reported or observed AEs are recorded by the investiga-
tors, and will be monitored until resolution, stabilisation 
or until it has been shown that the study intervention is 
not the cause. The National Cancer Institute Common 
Terminology Criteria for Adverse Events, V.4.03 (NIH 
publication # 09–7473), will be used to grade the severity 
of AEs. Gastrointestinal side effects (nausea, vomiting, 
abdominal pain, number of stools per week, stool type 
(Bristol Stool Chart), blood or mucus in the stool) will be 
registered by the patients once a week for the first month 
following the randomised intervention. Routine blood 
screening for MTX toxicity will normally be performed at 
weeks 4, 10, 16, 22 but can be more frequent if decided 
by the responsible treating rheumatologist depending 
on symptoms or signs of MTX toxicity. Subject incidence 
rates of all treatment-emergent AEs will be tabulated by 
system organ class and preferred term. Tables of fatal AEs, 
SAEs, AEs leading to withdrawal from study and signif-
icant treatment-emergent AEs, will also be provided. 
For the long-term extension portion of this study, expo-
sure-adjusted event rates will be summarised.
Sample size and power considerations
When designing this trial, no prior data for FMT effi-
cacy in patients with rheumatic disease were available. 
However, we found it reasonable to assume that if patients 
with rheumatic disease should be willing to receive FMT 
as a future standardised treatment, the procedure should 
at least provide an effect size well beyond a moderate 
effect size. Consequently, we decided that at least twice 
as many patients with PsA in the sham group should be 
treatment failures compared with the FMT group if the 
procedure should be considered clinically relevant. For 
a comparison of two independent binomial proportions 
using the Pearson's Χ2 statistic with a Χ2 approximation 
(a two-sided significance level of 0.05), a sample size of 40 
patients with PsA per group has a power of 90% (0.895), if 
we assume that the proportions of treatment failures are 
35% (FMT-active group) and 70% (FMT-sham group), 
respectively. Consequently, the inclusion of 80 patients 
with PsA allocated (1:1) to two treatment arms is believed 
to be sufficient to reveal any difference of clinical impor-
tance between treatment groups (ie, an Number needed 
to treat (NNT) <3 patients).
Assuming that there will be some attrition during 
the 6-month trial period, we also estimated how much 
dropout would be possible while still having a reasonable 
statistical power (80%): a total sample size of 62 patients 
with PsA assuming a comparable level of withdrawals (31 
patients completing in each group) achieves a power of 
at least 0.8 with the proportion of treatment failures indi-
cated above, that is, even if we experience a dropout rate 
of 20%, our trial will have 80% chance of detecting the 
intentional difference between groups.
Beyond the primary end point, a total sample size of 
80 (with a balanced design) corresponds to a sufficient 
statistical power (82%) to detect a standardised mean 
difference of 0.65 SD units (ie, Cohen's effect size) in any 
of the patient-reported outcome measures.
Randomisation, allocation concealment and blinding
The randomisation has been conducted using central-com-
puter randomisation. Patients are randomly allocated 
(1:1) to receive either an FMT or a placebo saline trans-
plant (sham procedure). The randomisation lists were 
Activity/assessment
Prestudy 
screening
Visit 1
Baseline
Weeks
1, 2 and 3
Visit 2
1 month
Visit 3
3 months
Visit 4
6 months
Sigmoidoscopy and mucosa biopsy x x
Stool, blood and urine samples (biobank) x x x x
Intestinal permeability test x x
Intervention (±FMT) x
Serious AE forms x
AE, adverse event; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI; Bath Ankylosing Spondylitis Functional Index; BASMI, 
Bath Ankylosing Spondylitis Metrology index; DLQI, Dermatology Quality of Life Index; HAQ, Health Assessment Questionnaire; HDL, high-
density lipoprotein; Hgb, haemoglobin; LDL, low-density lipoprotein; SPARCC, Spondyloarthritis Research Consortium of Canada; TSH, 
thyroid-stimulating hormone; VAS, visual analogue scale.
Table 1 Continued 
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generated by the trial statistician and uploaded to the 
REDCap database by an independent data manager who 
is not involved in any other aspects of the trial. Eligible 
patients will, after signing informed consent, be assigned 
randomly in permuted blocks with varying sizes of 4 and 
6, according to computer-generated random numbers 
(SAS programming via SAS PROC PLAN), to undergo 
either FMT or saline (sham) procedure using stratifica-
tion for centre. The randomisation of each patient will 
be implemented by the local trial coordinator and allo-
cation will be concealed as this is done independent of 
the predetermined sequence generation (ie, randomis-
ation). The patients, care providers and outcome asses-
sors will remain unaware of the group assignments, and 
only de-identified codes will be used to link participants 
to their data during the study to maintain their confiden-
tiality. In case of exceptional circumstances when knowl-
edge of the treatment allocation is essential for further 
management of the patient, the trial secretary will reveal 
the assigned intervention to the treating doctor. However, 
patients, trial care providers and outcome assessors will 
remain blinded as far as possible. Cases of unblinding will 
be registered and reported.
data collection, management and confidentiality
Data will be entered via a secure web-based electronic 
clinical report form into a central REDCap94 database 
hosted by Odense Patient data Explorative Network at 
Odense University Hospital. Data obtained during the 
clinical examination will be entered directly into the 
database. Also, patient questionnaires will be fulfilled 
directly into the database. Access to the study data will be 
restricted, and a password system will be used to control 
access. All information about the patients’ health and 
other private matters is covered by confidentiality. The 
authorisation from the Danish Data Protection Agency 
has been secured.
Statistical methods
The full analysis set will consist of all randomised partici-
pants (ie, the intention-to-treat (ITT) population): partic-
ipants will be analysed according to their randomised 
treatment group, that is, the ITT has the consequence 
that participants allocated to a treatment group will be 
followed up, assessed and analysed as members of that 
group irrespective of their compliance to the planned 
treatment. The safety analysis set will include all patients 
who were randomly assigned to a study group and had 
exposure to a transplant (independent of group). Descrip-
tive statistics will be provided for demographics and base-
line characteristics. The summary statistics of continuous 
variables will include: N, mean, SD, median, interquar-
tiles and range. All summaries presenting frequencies 
and incidences will include counts, percentages and the 
total number of participants in the corresponding arm.
The prespecified efficacy analyses will be based on 
data from the full-analysis set, which include all patients 
who underwent randomisation, have had their baseline 
measurement performed and who have received the 
initial transplant (independent of group). Although 
proper random assignment prevents selection bias, it 
does not guarantee that the groups will be equivalent at 
baseline. Any differences in baseline characteristics are, 
however, the result of chance rather than bias95; thus, the 
study groups will be evaluated (and presented) at baseline 
for important demographic and clinical characteristics 
so that readers can assess how similar they are. However, 
only cohort studies can be subject to selection bias and 
confounding due to differences in baseline characteris-
tics between the intervention and comparison groups.96
Our strategy for ITT analysis with incomplete observa-
tions will be based on the recommendations from White 
et al97:
1. Attempt to follow-up all randomised participants, 
even if they withdraw from allocated treatment.
2. Perform a main analysis of all observed data (data as 
observed).
3. Perform sensitivity analyses to explore the effect of de-
partures from the assumption made in the main anal-
ysis (Baseline Observation Carried Forward (BOCF) 
imputations, repeated measures mixed models and 
multiple imputations).
This results in the following steps: missing values will be 
imputed with the use of a non-responder imputation by 
use of the BOCF method for measurements made after 
baseline. Thus, missing data for dichotomous endpoints 
will also be imputed using a conservative ‘null responder’ 
imputation, assuming the patient did not have any benefit 
from being enrolled in the trial (eg, for the primary 
end point we will assume that the patient had a treatment 
failure which is valid based on clinical judgement even if 
data are not missing at random). Other sensitivity anal-
yses will be including ‘worst’ and ‘best’ case imputation, 
repeated-measures and multiple-imputation analyses, 
using model-based approaches; repeated measures linear 
mixed models will also be used to model the potential 
group-dependent trajectories over time (ie, repeated 
mixed models and multiple imputation are valid if data 
are assumed missing at random).
Categorical data for dichotomous end points will be 
analysed with the use of logistic regression with the model 
including treatment and centre as class effects. For contin-
uous outcome measures, analysis of covariance models 
will be used to analyse mean changes in continuous end 
points. All models will include treatment, centre, with the 
baseline value of the relevant variable as covariates.
Additionally, completer analyses will be performed 
on those who complete 6 months of treatment. During 
follow-up, any medical treatments which could potentially 
modify the intestinal microbiota including antibiotics 
will be reported, but will not affect the statistical anal-
ysis. Statistical estimates will be calculated as ORs for the 
dichotomous variables and difference between means for 
continuous outcomes reported with 95% CIs. Two-sided 
95% CIs and P values for primary, secondary and explor-
atory outcomes will be computed and will not be adjusted 
 o
n
 2 M
ay 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019231 on 27 April 2018. Downloaded from 
10 Kragsnaes MS, et al. BMJ Open 2018;8:e019231. doi:10.1136/bmjopen-2017-019231
Open Access 
for multiplicity, but will be interpreted cautiously as this is 
an exploratory trial per se.
Prespecified exploratory analyses: stratified analyses 
will investigate whether the treatment effect varies with 
i) the faecal microbiota analyses performed at follow-up 
compared with baseline (±long-term changes in the 
intestinal microbiota and intestinal inflammation) and 
ii) the demographic match (sex, age) between the stool 
donor and the recipient. Non-responders will represent 
the outcome group not fulfilling the primary outcome 
measure. Differences in demographics and baseline 
disease activity between this treatment-failure subpop-
ulation and the remaining group will be examined to 
identify potential prognostic factors for poor responders. 
Patients not participating in the follow-up examination 
will be classified as ‘dropouts’, and if possible, the reason 
for not participating will be registered.
Metagenomics analysis will be performed as described 
in the section on collection of faecal samples.72 73 74 To 
identify possible associations, metagenome analysis will 
be correlated to all clinical parameter. We will use an L1 
restricted least absolute shrinkage and selection operator 
(LASSO) procedure to determine the optimal number of 
features to be tested as described. Analysis of correlations 
between microbiota taxonomic or functional features, 
community diversity indices and sample metadata vari-
ables will be performed using Spearman's correlation 
tests corrected for multiple tests using the Benjami-
ni-Hochberg false discovery rate control procedure. To 
control for confounders, we will use blocked Spearman's 
correlation tests.98 99
Data will be analysed with the STATA statistical package 
(V.15; StataCorp), and SAS software (V.9.4; SAS Institute, 
Cary, North Carolina, USA).
EThICS And dISSEMInATIon
This study is designed as a proof-of-concept clinical trial 
and will be performed in agreement with Good Clinical 
Practice (GCP) standards, and in accordance with the 
ethical standards of the responsible committee on human 
experimentation (institutional and national) and with the 
Helsinki Declaration (64th, 2013). The relevance of the 
study, the design and the recruitment strategy were eval-
uated with three patient research partners (PRPs), and 
alterations especially in primary outcome and recruit-
ment strategy were embedded. Furthermore, a minimum 
of two PRPs (participating in the study) will be involved 
in the discussion regarding the progress of the recruit-
ment phase and results, and will be offered the opportu-
nity to comment on the manuscript draft. The trial has 
been registered with  ClinicalTrials. gov (NCT03058900) 
and important protocol modifications will be updated 
here. The Danish Health and Medicines Authority does 
not classify the FMT procedure as a medical intervention, 
and has had no objection to the use of FMT for this study 
and patient category. Thus, no GCP auditing is legally 
required. A report describing any potential side effects 
and AEs will be submitted to the Ethics Committee yearly. 
Suspected Unexpected Serious Adverse Reactions will be 
reported to the Ethics Committee within 7 days. Based 
on these reports, the Ethics committee can determine 
to terminate the trial early. The Danish Patient Compen-
sation Association provides compensations for patients 
injured in connection to medical clinical trials.
Although the Danish Health Authorities, for the time 
being, do not classify donor faecal microbiota as tissue, all 
steps of the stool donor recruitment, stool donation and 
FMT preparation will be in accordance with the Danish 
Tissue Law to ensure that the quality and safety stan-
dards laid down in the Danish Legislation BEK nr 764 of 
26 May 2015 (implementing Directive 2004/23/EC) are 
met. Four stool donors will be recruited from the South 
Danish Transfusion Service & Tissue Centre, Department 
of Clinical Immunology, Odense University Hospital, and 
they will be carefully screened for potentially transmis-
sible infections and other conditions associated with gut 
microbiota function before their stool can be released for 
FMT. Being a stool donor is voluntary, and no compen-
sation fee will be given. Furthermore, to ensure donor 
traceability, each patient in the active treatment arm will 
only receive microbiota from one donor. Also, frozen 
samples will be clearly labelled with a unique donation 
code based on the ISBT 128 coding and labelling system, 
and the release of the final product will adhere to the 
standards for tissue and blood donation.
Due to the well-documented risk of permanent joint 
destruction and occurrence of extra-articular manifes-
tations in the PsA disease course, identification of new 
treatment modalities and biomarkers is essential to help 
the physician to slow down the disease development or 
ultimately to prevent it. All patients with PsA participating 
in this study have significant activity in their joint disease 
despite treatment with the current guideline treatment 
and first-line drug, MTX, for this condition. This patient 
population will therefore benefit greatly from new treat-
ment options. Consequently, when weighing the pros and 
cons, this trial should be performed from a scientific and 
ethical perspective.
Dissemination will occur through presentations at 
national and international conferences and publications 
in international peer-reviewed journal(s).
dISCuSSIon
Recent years have seen growing recognition of the 
complexity of the role of the microbiota in shaping the 
immune system and its potential effects for health and 
disease.22 100 101 In particular, the gut bacterial composi-
tion has been associated with the pathogenesis of auto-
immune and inflammatory diseases.102–105 Intriguingly, 
an abnormal intestinal bacterial composition has been 
observed in patients with PsA, and this association has 
fostered theories linking intestinal dysbiosis and PsA joint 
inflammation.106 Still, it remains to be elucidated whether 
the intestinal dysbiosis and rheumatic diseases are causally 
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related,55 and if so, whether dysbiosis is an inciting event 
in the inflammatory process or a consequence of local 
and/or systemic inflammation.54 107 We expect that this 
double-blind, randomised, placebo-controlled trial will 
shed new light on this highly relevant topic.
This is the first time that the efficacy and safety of FMT 
is being investigated in MTX immunosuppressed patients 
with rheumatic diseases. Subsequently, no data on the 
feasibility of conducting FMTs in the rheumatological 
setting is, so far, available. Nor do we know whether one 
FMT will be sufficient, or whether it should be repeated 
shortly after the first intervention to normalise the alter-
ations of the intestinal microbiota, which would expect-
edly enhance any potential anti-inflammatory effects. In 
the present proof-of-concept clinical trial, the FMT proce-
dure is considered an add-on to the current guideline 
intervention and first-line drug, MTX. Therefore, from 
a pragmatic and ethical perspective, we have decided 
to perform only one FMT (or sham procedure) in each 
patient even if we are well aware that this approach may 
not be adequate to achieve long-lasting effects. Indeed, in 
patients with IBDs it appears that performing a frequent 
dosing regime repeating the FMT procedure up to five 
times a week for 8 weeks provided the best results.51 108 109 
Hence, in contrast to the treatment of C. difficile infec-
tions where the microbiota is pushed past the point of 
homeostasis and can be restored following only one 
FMT,47 the chronic nature of PsA and other autoimmune 
and inflammatory diseases, and the somewhat lesser 
degree of intestinal dysbiosis, may make the host micro-
biota more resistant to long-lasting modifications. Never-
theless, we hope that the FMT procedure in the present 
study will be sufficient to boost the effects of MTX so that 
the participants who are all MTX non-responders prior 
to study enrolment will achieve disease control without 
needing to add or switch to other non-MTX medication.
In the present trial, the primary outcome measure is 
defined as the occurrence of treatment failure according 
to shared decision-making between patient and physician 
evaluated at 6 months following the randomised interven-
tion (FMT vs sham procedure). Shared decision-making 
is a process in which both patient and health professional 
make a decision, taking into account the best evidence of 
available treatment options and the patient’s values and 
preferences. This approach is considered a key element 
in the management of rheumatic diseases.110 As both 
patients and the treating rheumatologists are blinded to 
the randomised intervention, the shared decision-making 
will be unaffected by the type of transplant suspension 
(active or placebo) installed at baseline. Nevertheless, 
we acknowledge that our assumption that twice as many 
patients with PsA in the sham group will be treatment 
failures is ambitious, and that we might miss a smaller 
and less clinically significant treatment effect of the 
FMT procedure. In this case, we hope that our secondary 
outcome measures will be able to detect potential trends 
of positive effects in PsA subdomains such as enthesitis 
score, dactylitis count and PASI skin score. In addition to 
the primary end point evaluation at 6 months, patients 
will be asked to fill out a weekly questionnaire regarding 
side effects as well as skin and arthritis symptoms during 
the first month following the randomised intervention 
to reveal any short-term effects on patient-reported 
outcomes.
Next, only patients with active peripheral PsA will be 
included. One reason for this is that this will be the first 
time that FMT is performed on patients with rheumatic 
disease. Therefore, it seems reasonable only to enrol 
patients who have had inadequate effect from the initial 
guideline treatment (MTX), and consequently, on an 
individual basis could benefit the most from participating 
in new experimental clinical trials. Also, since patients 
need to have at least three swollen joints, we expect that 
we will be able to detect treatment effects of clinical 
importance. The fact that we do not include recent-onset 
treatment-naïve patients will, of course, limit our ability 
to generalise our findings unto the entire patient popula-
tion with PsA. Indeed, in a recent randomised controlled 
trial of FMT in patients with ulcerative colitis, participants 
with a recent diagnosis (<1 year) were statistically signifi-
cantly more likely to respond to FMT compared with those 
with longer disease duration.108 That patients will have 
to subcutaneously administer MTX for at least 3 months 
prior to study enrolment will ensure that low intestinal 
MTX absorption is excluded as a potential effect modifier 
for the poor MTX response. In addition, as many drugs, 
including MTX, seem to affect the intestinal microbio-
logical milieu,111–114 bypassing the intestine during MTX 
administration will ensure that no local non-disease-re-
lated effects on the intestinal microbiota will occur.
A great challenge when conducting a trial of FMT is 
that for the present being there is a lack of both national 
and international recommendations guiding the regula-
tion and the best clinical practices for donor screening, 
stool sample handling and preparation of the FMT 
suspension.115–117 Indeed, the variability in faecal bacte-
rial communities can complicate or undermine treat-
ment efficacy. This variability stems from both biological 
variation and variation introduced by sample handling. 
A recent study reported that oxygen exposure degraded 
faecal bacterial communities, whereas freeze-thaw cycles 
and lag time between donor defaecation and transplant 
preparation had much more limited effects.118 Given 
that many intestinal bacteria are obligate anaerobe, 
including many beneficial bacteria potentially possessing 
anti-inflammatory effects, exposure to oxygen during 
the preparation of FMT may potentially compromise the 
therapeutic value of FMT in PsA and other inflammatory 
diseases. Therefore, although frozen faecal preparations 
of stool suspended into physiological saline and glycerol 
have proven just as effective as fresh stool in treating C. 
difficile infections,119 the optimal transplant preparation 
method in treating inflammatory diseases remains to be 
established.
Our stool handling setup is in line with the prevailing 
practice, which includes mixing and filtration of the stool 
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suspension and adding saline and glycerol as a cryopre-
servative before storage at −80°C.117 In addition, we have 
sought to limit the oxygen exposure during transport 
by placing the donor stool within a plastic bag, which 
is subsequently put into a tightly closed small plastic 
container. Supplementary, during preparation the solu-
tion will not be homogenised for more than 10 s. Never-
theless, the lack of optimal anaerobe conditions during 
stool handling could possibly undermine the therapeutic 
potential of our FMT procedure. Furthermore, although 
we aim to use 50 g of faeces for each transplant, we 
acknowledge that the exact weight between donations 
could vary with an estimated ±5 g. Also, due to the wide 
variability in microbial content in stool between dona-
tions, the content cannot be fully standardised, and may 
likely differ between each FMT procedure. However, to 
meet this challenge we will collect and store samples from 
each donation which will enable us to determine the 
microbiota composition of each donation in case some 
donations prove more effective than others.
Stool donor selection is another critical issue that needs 
to be addressed. The composition of the normal microbiota 
composition has only recently been mapped,74 and the exis-
tence of a limited number of well-balanced host–microbial 
symbiotic states, where one or more bacteria species are 
considered the main functional driver(s), have been identi-
fied using clustering of metagenomic sequences.120 Still, the 
most favourable donor microbiota composition for treating 
inflammatory diseases has yet to be determined. Therefore, 
it also remains to be established whether donors with a high 
stool bacteria diversity should be preferred over isolation 
of specific bacteria, or if pooled stool samples from several 
donors outperforms a single-donor transplant.51 121 We have 
chosen to use only single donations from four different 
anonymous stool donors to ensure donor traceability and to 
enable us to identify any individual donor-specific microbial 
effects. Also, since host intrinsic, environmental and dietary 
factors as well as pharmaceutical drugs have been associated 
with gut bacterial composition and functionality,111 112 122 123 
the donors must eat a balanced diet, not be overweight or 
take any medications or be physically or psychologically 
stressed, smoke or consume alcohol during the donation 
period to limit the risk of transferring ‘abnormal’ micro-
biota to the recipients. These donor criteria have been 
set for safety reasons, and we acknowledge that this could 
potentially limit the interdonor microbiota diversity due to 
shared lifestyle characteristics.
Another factor to keep in mind is the concept of 
matching donor and recipient, which may be of impor-
tance for enhancing the colonisation capabilities of the 
donor microbial communities. In fact, Rossen et al109 did 
find that in patients with ulcerative colitis, the microbiota of 
FMT responders shifted to their respective donors, whereas 
non-responders did not. Li et al124 reported that donor 
bacteria strains established extensively in the recipient and 
persisted for at least 3 months with a negligible decline of 
donor-strain populations detected between 45 days and 3 
months following FMT in patients with metabolic syndrome. 
However, they also found that recipients receiving the same 
donor transplant displayed varying degrees of microbiota 
transfer, indicating individual patterns of microbiome resis-
tance and donor-recipient compatibilities. In addition, 
host genetics is known to effect the gut microbiota,125 and 
animal models have shown that sex126 and age127 also can 
be potentially modifiers of the gut bacteria composition. 
These observations may prove to be of importance for the 
outcome of FMT in inflammatory diseases.128 However, 
whether sex-matching and/or age-matching between donor 
and recipient is crucial for a successful FMT in humans 
remains to be enlighten. Therefore, in the present study, 
no donor-recipient matching will be conducted. However, a 
subgroup analysis will be performed to reveal any trend that 
could indicate better results in sex-matched or age-matched 
cases.
Furthermore, as the interactions between the microbiota 
and the host are influenced by cooperation and competi-
tion between pathogenic and commensal microbes and 
multiple environmental variables, the lifestyle of the recip-
ient following the FMT may be of importance. Neverthe-
less, due to the uncertainty of how to define the optimal 
lifestyle and the lack of knowledge on how different lifestyle 
factors may interfere with the microbiota, we have decided 
that the patients in the present study will not have to adhere 
to any predefined lifestyle ‘regime’ or diet following the 
randomised intervention. However, every participant will 
fulfil an eating habit questionnaire at the beginning of the 
trial.
Finally, non-bacteria microorganisms such as bacte-
riophages, viruses and fungi may also be of importance 
when targeting components of the microbiota or host 
cells for therapeutic purposes.129–131 Other compli-
cating factors may include the composition of other 
microbiological niches such as the oral, lung, genitouri-
nary and skin microbiota.132 133 Indeed, the latter could 
likely prove to be of significance in patients with skin 
psoriasis. However, these factors will not be assessed in 
the present study.
In conclusion, this trial has the potential to substan-
tially expand the growing body of literature on the role 
of the intestinal microbiota in general and in PsA in 
particular. Furthermore, we anticipate that this study 
will enhance our understanding of cause and effect. The 
results of this study, when completed, may be exploited 
for biomarker discovery, and for diagnostic and thera-
peutic purposes.
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